Solta Medical, Inc. (Nasdaq: SLTM) today announced the donation of a Fraxel re:store laser system to the Grossman Burn Foundation, the philanthropic arm of the Grossman Burn Center, a worldwide leader in innovative treatment and care for burn patients and their families. The Fraxel re:store system will be used to reduce the appearance of scarring caused by traumatic thermal damage.
"Solta Medical is pleased to donate a Fraxel re:store system to the Grossman Burn Foundation to treat patients' scars and help in their recovery," said Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. "The Grossman Burn Foundation is well known for their humanitarian efforts to assist burn victims and their families throughout the world, and we applaud their efforts to provide highly-skilled non-profit reconstructive surgery."
Fraxel re:store laser treatment resurfaces damaged skin to uncover the smoother, healthier skin underneath. For burn victims, Fraxel re:store treatment penetrates the outer layers of damaged skin (epidermis) and reaches deeper layers of skin (dermis) where collagen and elastin are located. The laser columns stimulate a natural healing process that produces new collagen to replace the damaged tissue with new, healthy skin cells, and improve the skin's overall tone and texture. As the original fractional laser technology, Fraxel re:store has been FDA-cleared to treat a number of skin conditions including: acne scars, surgical scars, actinic keratoses, age spots/sunspots, melasma and wrinkles around the eyes.
"We are extremely grateful for this generous and important donation by Solta Medical," said Rebecca Grossman, Chair of the Grossman Burn Foundation. "The goal of restorative burn care is to return the patient to as close to pre-injury status as possible. Often that requires multiple surgeries combining both reconstructive and aesthetic work. We plan to use the cutting-edge Fraxel technology to restore our burn-injured patients and play a key role in providing better and faster patient outcomes."
SOURCE Solta Medical, Inc.